Belfast company secures multi-million pound US deal to advance oncology precision medicine.
The Belfast-based pharmaceutical technology company Diaceutics secured a multi-million pound contract with Partner Therapeutics to develop precision oncology medicine while expecting more than £4.5 million in recurring revenue from BIZENGRI brand sales.
The company which operates in the pharma and biotech sector predicts this partnership will enhance its service capabilities. The CEO of Diaceutics Ryan Keeling demonstrated his excitement about the company's partnership with Partner Therapeutics to deliver essential therapy to patients who need it. The platform will enable them to rapidly detect and link patients with their most suitable oncology treatment options. The team at Partner Therapeutics recognizes both the innovative aspects of PMx and its ability to boost BIZENGRI's success.
The commercialization tools from PMx will be used by Partner Therapeutics to support the therapy which had its previous US license holder. The PMx platform from Diaceutics enables patient profiling for genomic matching to speed up treatment access.
Shandor Brenner is an American journalist recognized for his sharp and insightful reporting on social and political issues. His work is known for its depth, integrity, and the ability to highlight critical societal concerns.